Company: HCWB
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-058961
Chunk: 35

Company: HCW Biologics Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 35
---
 Technology.

<div align='center'>24</div>

TABLE OF CONTENTS

EXECUTIVE COMPENSATION We became a public company in July 2021, and we are an “emerging growth company” under applicable federal securities laws and therefore permitted to take advantage of certain reduced public company reporting requirements. As an emerging growth company, we provide in this proxy statement the scaled disclosure permitted under the Jumpstart Our Business Startups Act of 2012, including certain executive compensation disclosures required of a “smaller reporting company,” as that term is defined in Rule 12b-2 promulgated under the Exchange Act. In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We will remain an emerging growth company until the earliest of (i) the last day of our fiscal year following the fifth anniversary of the completion of our initial public offering, (ii) the last day of the first fiscal year in which our annual gross revenue is $1.235 billion or more, (iii) the date on which we have, during the previous rolling three-year period, issued more than $1 billion in non-convertible debt securities, or (iv) the date on which we are deemed to be a “large accelerated filer” as defined in the Exchange Act. Named Executive Officers Our named executive officers for 2024, which consist of our principal executive officer and the next two most highly compensated executive officers, are: Hing C. Wong, Ph.D., our Founder and Chief Executive Officer; Rebecca Byam, our Chief Financial Officer; and Peter Rhode, Ph.D., our Chief Scientific Officer and Vice President of Clinical Operations. Summary Compensation Table The following table provides information concerning compensation awarded to, earned by and paid to each of our named executive officers during 2023 and 2024:

| Name and Principal Position                                        
 Hing C. Wong, Ph.D.                                                | Fiscal Year | Salary($) |         |     | Bonus($) |       |     | Option Awards($)(1) | Non-Equity Incentive Plan Compensation ($)(3) | All Other Compensation ($)(2) |        |     | Total($) |         |
|:-------------------------------------------------------------------|------------:|:----------|--------:|:----|:---------|------:|:----|:--------------------|:----------------------------------------------|:------------------------------|-------:|:----|:---------|